Pulmonary fibrosis

Prescribing Notes:

Due to different formulations of nintedanib being licensed for different indications, prescribe by brand name only.
Before initiating systemic vascular endothelial growth factor (VEGF) pathway inhibitors (nintedanib), carefully consider the risk of aneurysm and artery dissection in patients with risk factors. In patients who receive a systemic VEGF pathway inhibitor, reduce as far as possible any modifiable risk factors such as hypertension. For further advice see MHRA Drug Safety Update (July 2020).
Serious liver injury has been reported in patients treated with pirfenidone. For further advice on liver function testing see MHRA Drug Safety Update (November 2020). This may also be relevant for patients treated with nintedanib.
Patients should be monitored on a regular basis. The need for ongoing treatment should be reviewed after 3 months and 12 months.

15/04/2026

Regional formulary chapter launched.

Due to different formulations of nintedanib being licensed for different indications, prescribe by brand name only.
Before initiating systemic vascular endothelial growth factor (VEGF) pathway inhibitors (nintedanib), carefully consider the risk of aneurysm and artery dissection in patients with risk factors. In patients who receive a systemic VEGF pathway inhibitor, reduce as far as possible any modifiable risk factors such as hypertension. For further advice see MHRA Drug Safety Update (July 2020).
For further advice on liver function testing see MHRA Drug Safety Update (November 2020). This may be relevant for patients treated with nintedanib.
Nintedanib is approved for use for the treatment of other chronic fibrosing interstitial lung diseases with a progressive phenotype.

15/04/2026

Regional formulary chapter launched.